These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 16158214

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model.
    Jauregizar N, Quintana A, Suarez E, Raczka E, de la Fuente L, Calvo R.
    Gerontology; 2003; 49(4):205-14. PubMed ID: 12792155
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M, Sologuren A, Valiente R, Smith J.
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN, Rohatagi S, Jensen BK, DePhillips SL, Rhodes GR.
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response.
    Bundgaard C, Larsen F, Kreilgaard M, Brennum LT, Olsen CK.
    Biopharm Drug Dispos; 2009 May; 30(4):209-20. PubMed ID: 19475539
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Functional group interactions of a 5-HT3R antagonist.
    Venkataraman P, Joshi P, Venkatachalan SP, Muthalagi M, Parihar HS, Kirschbaum KS, Schulte MK.
    BMC Biochem; 2002 Jun 13; 3():16. PubMed ID: 12079499
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.
    Bertera FM, Mayer MA, Opezzo JA, Taira CA, Bramuglia GF, Höcht C.
    J Pharmacol Toxicol Methods; 2007 Jun 13; 56(3):290-9. PubMed ID: 17560132
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW, Liu DN, Yan LH, Cui XY, Zhang KP, Qi C, Chen J.
    Pharmacol Biochem Behav; 2006 Oct 13; 85(2):464-73. PubMed ID: 17126387
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, Belvin M, Prescott J.
    Clin Cancer Res; 2012 Jun 01; 18(11):3090-9. PubMed ID: 22496205
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.
    Kumar Puttrevu S, Ramakrishna R, Bhateria M, Jain M, Hanif K, Bhatta RS.
    Naunyn Schmiedebergs Arch Pharmacol; 2017 May 01; 390(5):457-470. PubMed ID: 28190245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.